BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20095057)

  • 1. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
    Lacy MQ; Rajkumar SV
    Am J Hematol; 2010 Feb; 85(2):95-6. PubMed ID: 20095057
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 3. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IMiDs in hematology].
    Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
    Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pomalidomide (Pomalyst) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
    Shortt J; Hsu AK; Johnstone RW
    Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thalidomide: mechanisms of action and new insights in hematology].
    Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
    Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pomalidomide: when expectations are understated.
    Di Raimondo F; Conticello C
    Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
    Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
    Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
    Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
    Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of multiple myeloma by immunomodulatory drugs].
    Hata H
    Rinsho Ketsueki; 2011 Oct; 52(10):1485-95. PubMed ID: 21971225
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
    Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
    Vivas AC; Chimento SM; Herschthal J; Spock C; Alonso-Llamazares J
    J Am Acad Dermatol; 2013 Jun; 68(6):e179-80. PubMed ID: 23680209
    [No Abstract]   [Full Text] [Related]  

  • 18. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
    Modi D; Mamdani H; Vettese T
    Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.